NO20062689L - Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer - Google Patents

Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer

Info

Publication number
NO20062689L
NO20062689L NO20062689A NO20062689A NO20062689L NO 20062689 L NO20062689 L NO 20062689L NO 20062689 A NO20062689 A NO 20062689A NO 20062689 A NO20062689 A NO 20062689A NO 20062689 L NO20062689 L NO 20062689L
Authority
NO
Norway
Prior art keywords
modulators
formula
cannabinoid receptors
compounds
azabicyclic
Prior art date
Application number
NO20062689A
Other languages
English (en)
Inventor
Bruce Ellsworth
William R Ewing
Guixue Yu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20062689L publication Critical patent/NO20062689L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)

Abstract

Foreliggende søknad beskriver forbindelser med formel I, farmasøytiske preparater omfattende minst én forbindelse med formel I og eventuelt ett eller flere ytterligere terapeutiske midler og metoder for behandling ved anvendelse av forbindelsene i henhold til Formel I både alene og i kombinasjon med ett eller flere ytterligere terapeutiske midler. Forbindelsene har den generelle formel I omfattende alle prodrug, farmasøytisk akseptable salter og stereoisomerer, R1, R2, R3 og R4 er beskrevet her.
NO20062689A 2003-12-19 2006-06-12 Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer NO20062689L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53145103P 2003-12-19 2003-12-19
PCT/US2004/042542 WO2005061509A1 (en) 2003-12-19 2004-12-20 Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
NO20062689L true NO20062689L (no) 2006-09-12

Family

ID=34710226

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062689A NO20062689L (no) 2003-12-19 2006-06-12 Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer

Country Status (11)

Country Link
US (1) US7037910B2 (no)
EP (1) EP1699796A4 (no)
JP (1) JP2007514756A (no)
CN (2) CN1918164A (no)
AR (2) AR046964A1 (no)
IS (1) IS8501A (no)
NO (1) NO20062689L (no)
PE (2) PE20051047A1 (no)
TW (2) TW200530246A (no)
WO (1) WO2005061509A1 (no)
ZA (2) ZA200604645B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
EP1430033A4 (en) 2001-08-31 2004-12-15 Univ Northwestern PROTEIN KINASE ANTI-INFLAMMATORY AND INHIBITOR COMPOSITION AND METHOD OF USE
PL1697371T3 (pl) 2003-12-19 2007-09-28 Bristol Myers Squibb Co Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
US20060025448A1 (en) * 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
ES2543813T3 (es) 2004-11-02 2015-08-24 Northwestern University Compuestos de piridazina para el tratamiento de enfermedades inflamatorias
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
AU2007239033B2 (en) 2006-03-30 2011-12-15 Irm Llc Azolopyrimidines as inhibitors of Cannabinoid 1 activity
WO2007127375A2 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
KR20090013815A (ko) * 2006-05-04 2009-02-05 솔베이 파마슈티칼스 비. 브이 충동 조절 장애의 치료를 위한 무스카린 작용제
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CA2684059C (en) * 2007-04-11 2016-07-12 Omeros Corporation Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009137337A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute STEREOSELECTIVE SYNTHESIS OF 17-α -AND 17-β -ARYL STEROIDAL COMPOUNDS
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
FR2958850B1 (fr) * 2010-04-14 2012-07-06 Centre Nat Rech Scient Medicaments pour la prevention ou le traitement des addictions aux drogues
EP2560949B1 (en) * 2010-04-20 2015-12-02 Università degli Studi di Roma "La Sapienza" Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
MX2016009896A (es) * 2014-01-29 2017-01-11 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregacion de proteina.
BR112018075039A2 (pt) * 2016-06-03 2019-05-14 The Trustees Of Columbia University In The City Of New York métodos de tratamento da síndrome de prader-willi
CN108178759B (zh) * 2018-01-05 2020-06-09 上海瑞纷医药科技有限责任公司 一种α-肾上腺素受体拮抗剂的合成方法
CN108498511A (zh) * 2018-04-21 2018-09-07 徐晶 一种治疗膝关节骨性关节炎的药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164198B (it) * 1983-04-28 1987-04-08 Isf Spa Preparazione di un derivato piridazinico farmacologicamente attivo
CA2346659A1 (en) 1998-10-06 2000-04-13 Michiyo Gyoten Condensed pyridazine compounds, their production and use
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
WO2003066061A1 (en) * 2002-02-07 2003-08-14 Pfizer Limited Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
DE60316416T2 (de) * 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
US7351826B2 (en) 2003-02-19 2008-04-01 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds

Also Published As

Publication number Publication date
ZA200604645B (en) 2007-11-28
CN1918164A (zh) 2007-02-21
CN1918165A (zh) 2007-02-21
JP2007514756A (ja) 2007-06-07
WO2005061509A1 (en) 2005-07-07
PE20050756A1 (es) 2005-10-06
IS8501A (is) 2006-06-08
TW200528455A (en) 2005-09-01
US7037910B2 (en) 2006-05-02
TW200530246A (en) 2005-09-16
EP1699796A1 (en) 2006-09-13
AR046964A1 (es) 2006-01-04
AR047063A1 (es) 2006-01-04
US20050192278A1 (en) 2005-09-01
EP1699796A4 (en) 2009-03-04
PE20051047A1 (es) 2005-12-16
ZA200604778B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
WO2005037199A3 (en) Pyrazole derivatives as cannabinoid receptor modulators
NO20045103L (no) Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse
NO20091247L (no) terapeutiske pyrazolyl tienopyridiner
NO20064010L (no) Indazolderivater og farmasoytiske preparater inneholdelse slike
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
NO20055143L (no) Doseringsformer innbefattende AG013736
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
NO20052182L (no) Nye forbindelser
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
DK2173749T3 (da) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamidderivater og beslægtede forbindelser som antisvampemidler
NO20055098L (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
NO20062307L (no) Spirofuropyridinarylderivater
DE602005005967D1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament
WO2006076569A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application